查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844198

感染疾病疫苗市场按疫苗类型、给药途径、最终用户和分销管道划分－2025-2032年全球预测

Infectious Vaccines Market by Vaccine Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，感染疾病疫苗市场规模将达到 669.8 亿美元，复合年增长率为 9.74%。

主要市场统计数据
基准年 2024 318.3亿美元
预计年份：2025年 348.8亿美元
预测年份：2032年 669.8亿美元
复合年增长率 (%) 9.74%

本文简要介绍了科学进步和不断发展的企业发展如何重塑感染疾病疫苗的研发管道和模式。

在科学创新、公共卫生优先事项的演变以及操作实践的改变的推动下，感染疾病疫苗领域正经历着变革时期。在过去十年间，mRNA和减毒活病毒疫苗载体等平台技术的进步已从实验性方法发展成为临床检验的工具，并在预防和治疗应用方面引起了广泛关注。同时，结合疫苗、灭活疫苗、减毒活疫苗、次单位疫苗和类毒素疫苗等现有疫苗也透过製剂改进、联合策略和标靶抗原工程不断发展。

新型製造技术、改进的低温运输管理和数位化供应链视觉化正在推动疫苗在不同医疗机构之间更可靠地分发。监管法规也不断调整以适应新型平台，同时保持严格的安全性和有效性标准。公共卫生计画也日益重视扩大疫苗覆盖范围和成人免疫策略。因此，从生物製药开发商到公共免疫项目，相关人员在重新调整产品开发、伙伴关係和部署计划，以兼顾技术前景和实际运作。

这项纳入构成了报告的核心，重点阐述了平台多样性、创新的管理途径、诊所、医院、药房和卫生中心等终端用户的动态变化，以及影响技术采纳和应用效果的分销机制。它为后续的详细分析奠定了基础，明确了科学机会与商业性和公共卫生需求之间的交汇点。

探讨推动疫苗研发和部署实务快速演变的技术、监管和物流变革的融合趋势

除了科学突破之外，感染疾病疫苗领域正受到一系列相互交织的变革的影响，这些变革影响着监管预期、供应链网络和医疗服务模式。首先，平台多样化正在加速。传讯RNA技术和病毒载体正从概念验证规模化生产阶段，而自扩增RNA和纯化脂质奈米颗粒製剂则正在拓展其适应症范围。成熟的疫苗平台，如结合疫苗、灭活疫苗和类毒素疫苗，也不断发展，透过抗原工程、佐剂优化和新型给药方式，提高了疫苗的免疫抗原性和持久性。

第二，给药途径的重要性日益凸显。虽然肌注在许多项目中仍占据主导地位，但皮内、鼻腔、口服和皮下给药途径因其能够提高患者接受度、简化物流并赋予粘膜免疫力而重新受到关注。第三，终端用户的细分正在影响分销策略。诊所、医院、药房和卫生中心各自存在不同的营运限制和机会，这些限制和机会影响包装、低温运输要求和数位记录的整合。第四，分销通路日趋专业化，政府采购、医院药局、线上药局和零售商都需要各自独特的商业性策略。

这些变化共同创造了一个动态的环境，在这个环境中，开发和分销的灵活性，加上战略伙伴关係和监管远见，将决定哪些项目能够获得广泛和持续的采用。

对 2025 年关税如何重塑疫苗生产和分销的供应链、筹资策略和采购动态进行实际评估。

2025年起对疫苗原料、组件及相关耗材征收关税，为生产商、经销商和采购机构带来了新的营运挑战。关税措施影响了整个价值链的单价结构，迫使生产商重新评估其全球筹资策略，尽可能优先考虑本地生产，并加快供应商资格认证流程以增强供应韧性。同时，采购机构和公共卫生采购人员也采取了相应措施，重新评估供应商多元化策略，并更加重视合约保障，以降低供应中断的风险。

关税也会影响通路的经济效益。医院药局、零售药局、网路药局和政府采购机构在采购决策中必须进一步考虑成本和合规性，这可能会改变进口产品与国产产品的相对吸引力。对于临床研发公司而言，关税带来的累积成本影响促使它们考虑建立区域性生产伙伴关係和技术转移协议，以降低关税波动带来的风险。

从下游角度来看，减少对专用低温运输组件和一次性给药装置依赖的给药途径可能更具实际吸引力，因为它们可以降低因辅助用品关税而导致成本增加的风险。整体而言，2025年的关税情势凸显了供应链透明度、合约弹性以及与采购机构积极沟通的重要性，这些措施对于在保障净利率和供应连续性的同时维持准入至关重要。

详细的细分洞察揭示了疫苗平台选择、给药途径、终端用户环境和分销管道如何相互作用，从而影响疫苗的普及率。

细分市场层面的动态反映了疫苗类型、接种途径、最终用户和分销管道的显着差异，了解这些差异对于策略优先排序至关重要。就疫苗类型而言，结合疫苗（包括Hib结合疫苗、脑膜炎双球菌结合疫苗和肺炎链球菌结合疫苗）对于儿童和高风险成人免疫计画仍然至关重要，因为长期免疫抗原性和人群保护是这些计画的重点。灭活疫苗，例如甲型肝炎疫苗、流感疫苗、脊髓灰质炎和狂犬病疫苗，由于其安全性已得到充分验证且监管法规已广泛认可，因此仍被广泛使用。活病毒疫苗，例如流感活疫苗、麻疹活疫苗、口服脊髓灰质炎疫苗、德国麻疹和水痘疫苗，能够提供强大的免疫反应，是大规模疫苗宣传活动的核心，但需要谨慎处理和低温运输管理。次单元疫苗，例如蛋白质次单元和类病毒颗粒构建体，具有良好的安全性和可生产性，而针对白喉、百日咳和破伤风的类毒素疫苗仍然是许多免疫接种计划的主要组成部分。腺病毒、MVA 和 VSV 等病毒载体因其能够诱导强效的细胞介导免疫，在预防和治疗方面仍被广泛应用。

在考虑给药途径时，可选择的途径包括皮内注射、肌肉注射、鼻内注射、口服和皮下注射，每种途径的操作要求和患者体验各不相同，这会影响诊所、医院、药房和卫生中心的采纳。与医院相比，全科诊所和专科诊所的容量和储存需求不同，私立和公立机构的采购和配製流程也不同。城乡都市区的公共卫生中心也面临不同的物流限制。分销管道，包括分为地方和国家级的政府机构、提供院内和门诊服务的医院药房、直接销售和透过平台销售的线上药房，以及分为连锁和独立模式的零售药房，进一步影响着商业性模式。这些细分维度相互影响。例如，成人肌肉注射的蛋白质次单元疫苗与透过国家公共卫生竞标采购的儿童鼻内注射减毒活疫苗，其分销和采购管道可能截然不同。

认识到这些相互依存关係，相关人员就可以调整其开发、製造和商业化策略，使其与目标细分市场的具体要求一致，从而加快产品推广速度，提高营运适应性。

关键的区域性因素解释了美洲、欧洲、中东和非洲以及亚太地区医疗基础设施和法规环境的差异将如何影响疫苗策略。

区域动态对产品设计、监管策略、製造地和部署重点有显着影响。在美洲，完善的免疫接种计划和发达的公立及私立医疗保健基础设施支撑着复杂的销售管道，包括医院药房以及广泛的零售和线上药房网络。因此，开发人员通常会优先考虑监管协调和支付方参与策略，这些策略既要体现民营市场机制，也要体现大规模公共医疗保健采购流程。

欧洲、中东和非洲的法律规范、公共卫生优先事项和供应链能力各不相同。欧洲部分地区拥有完善的监管管道和製造群，能够快速部署新型平台；而中东和非洲地区则可能优先考虑耐热配方、简化的给药途径以及有助于提升本地能力以应对获取限制的伙伴关係模式。该地区都市区医疗中心需要灵活的低温运输解决方案和部署策略，以适应不断变化的基础设施条件。

亚太地区蕴藏着巨大的频谱，从先进的製造地到快速发展的公共卫生体系，不一而足。拥有强大生物技术生态系统的国家正大力投资mRNA、病毒载体和下一代生产能力，而其他国家则专注于利用成熟的结合疫苗、灭活疫苗和类毒素疫苗扩大常规免疫覆盖范围。在全部区域策略是任何疫苗计划的核心要素，因为区域优先事项会影响产品规格、监管时间表和供应链投资。

从策略层面整合公司和合作伙伴如何协调平台投资、製造能力和协作生态系统，以确保竞争优势。

生物製药、生物技术和受託製造领域的领导企业正透过平台投资、策略联盟和产能扩张等方式重新定义其竞争地位。一些研发企业专注于平台可扩展性，致力于建构平台（例如mRNA、病毒载体和蛋白质次单元）的再利用能力，以适应多种适应症，从而最大限度地提高研发效率。受託製造企业正在扩展灌装和模组化生产能力，以满足对传统和新型疫苗的需求，同时专注于低温运输创新和一次性使用技术。

大型製药企业、区域製造商和技术专家之间的合作有助于技术转移、在地化生产和监管联络。同时，脂质奈米颗粒、佐剂和分析服务的专业供应商作为策略伙伴的重要性日益凸显，他们提供的关键投入会影响产品的性能和可生产性。能够支持加速临床试验流程和跨多个司法管辖区申报准备工作的临床和监管咨询公司也是宝贵的合作伙伴。

最后，整合免疫登记、不利事件监测和流行病学数据的监测和真实世界证据提供者正成为企业展现价值、优化核准后计画以及支持定向疫苗宣传活动的战略资产。总而言之，这些趋势凸显了在复杂且快速变化的环境中保持竞争力，需要采取协调一致的伙伴关係、能力规划和技术投资。

透过平台灵活性、製造韧性和有针对性的商业性合作，提出切实可行的建议，以提高采用率并降低营运风险。

产业领导者应采取多维策略，平衡技术创新、营运韧性和市场化部署。优先考虑平台灵活性，使他们能够将研发资源轮调用于不同适应症，并快速应对新出现的病原体威胁。同时，投资于製造韧性，例如本地化生产、多元化的供应商网路以及模组化填充包装能力，可以降低因外部衝击和关税造成的成本波动风险。领导者还应评估能够降低物流复杂性、提高患者接受度并支持本地无针给药方案的给药途径创新。

在商业性，根据特定终端使用者和通路需求调整分销策略能够加速产品推广。例如，儘早与医院配药委员会、零售药局连锁和公共卫生采购负责人接洽，可以明确储存和包装要求，从而体现在定价和合约条款中。积极与监管机构沟通，并投资开发统一的附加檔，可以加快产品在多个司法管辖区的核准流程。最后，建立数据伙伴关係关係，进行上市后监测和真实世界疗效监测，能够更好地展现产品价值，并支持产品的持续推广。

平台的多功能性、供应链的稳健性、有针对性的商业性合作以及对证据产生的承诺相结合，使行业领导者能够调整其产品组合，抓住临床和公共卫生机会，同时降低营运风险。

对用于评估疫苗项目平台性能、供应链风险和相关人员细分的研究资讯来源和分析方法进行透明概述

该研究结合了公开的科学文献、监管指导文件、行业技术报告以及对研发、生产、监管事务和采购领域专家的结构化访谈。主要定性资讯是透过与疫苗研发负责人、製造外包组织、供应链专业人员和公共卫生采购负责人的讨论收集的，以了解营运实践和策略重点。次要研究包括同行评审期刊、监管通告和技术白皮书，重点关注平台技术、给药途径和分销创新。

分析方法包括平台比较评估、供应链风险映射和相关人员细分，旨在识别疫苗类型、接种途径、最终用户需求和分销管道之间的关键相互依存关係。此外，还进行了情境评估，以评估关税等政策变化对营运的影响，并考虑本地化、供应商多元化和替代包装策略等策略性应对措施。在条件允许的情况下，研究结果经过资讯来源交叉检验，以确保其可靠性。同时，也召开了专家检验会议，以完善关键见解和切实可行的建议。

这种方法提供了技术可能性、营运限制和商业性路径的整体情况，使决策者能够得出切实可行的策略和投资结论，而无需依赖专有的市场估算。

总结报告强调，需要製定综合性的科学、製造和商业策略，才能将技术进步转化为对公共卫生的实质影响。

感染疾病疫苗处于快速发展的科学、政策和物流的交汇点，其成功取决于技术能力与实际发行策略的整合。从结合疫苗和灭活疫苗到mRNA、病毒载体、次单元构建体和类毒素，多种平台为满足未被满足的需求提供了多种途径。然而，这些科学机会必须与实际操作相平衡，包括低温运输限制、采购机制和监管环境。

诸如2025年关税等政策措施的累积影响凸显了供应链透明度和弹性采购方式的必要性。基础设施和监管成熟度的区域差异进一步强调了製定地域性策略的重要性。最终，那些选择符合终端用户需求的平台、投资于具有韧性和可扩展性的製造能力，并积极与支付方和公共卫生相关人员互动的组织，将更有能力将科学进步转化为广泛且可持续的公共卫生影响。

这个结论强调，研发、生产和商业部门之间的协调行动对于发挥下一代疫苗的潜力至关重要，同时也要确保公平可靠的取得途径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • mRNA疫苗技术的进步使得针对特定感染疾病的疫苗能够快速研发。
  • 扩大耐热疫苗配方规模，以支持在资源匮乏地区分发感染疾病疫苗
  • 将新一代佐剂整合到感染疾病疫苗中，以增强其免疫抗原性和持久性。
  • 多病原体联合疫苗的出现简化了全球免疫接种计划
  • 加强公私合营，为感染疾病疫苗研发提供资金并加速研发进程。
  • 利用基因组监测数据指导疫苗株的即时选择和更新策略
  • 引入数位化低温运输监控解决方案，以确保疫苗在整个分销网络中的有效性
  • 不断完善的法规结构旨在加速创新感染疫苗平台的审查和核准

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 按疫苗类型感染疾病疫苗市场

  • 共轭物
    • Hib 结合物
    • 脑膜炎双球菌结合物
    • 肺炎链球菌结合物
  • 惰性
    • 甲型肝炎
    • 流感
    • 脊髓灰质炎
    • 狂犬病
  • 减毒活活病毒疫苗
    • 流感病毒
    • 麻疹
    • 口服脊髓灰质炎
    • 德国麻疹
    • 水痘
  • mRNA
    • 脂质奈米颗粒mRNA
    • 自扩增mRNA
  • 次单元
    • 蛋白质次单元
    • 类病毒颗粒
  • 类毒素
    • 白喉
    • 百日咳
    • 破伤风
  • 病毒载体
    • 腺病毒
    • MVA
    • VSV

第九章 依给药途径分類的感染疾病疫苗市场

  • 皮内注射
  • 肌肉内注射
  • 鼻内
  • 口服
  • 皮下

第十章 按最终用户分類的感染疾病疫苗市场

  • 诊所
    • 一般医疗
    • 专业
  • 医院
    • 私人的
    • 公共
  • 药局
    • 在线的
    • 零售
  • 公共卫生中心
    • 遍远地区
    • 都市区的

第十一章感染疾病疫苗市场（依分销管道划分）

  • 政府机构
    • 当地的
    • 全国
  • 医院药房
    • 在医院里
    • 门诊
  • 网路药房
    • 直接地
    • 平台
  • 零售药房
    • 链
    • 独立

第十二章 各地区感染疾病疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章感染疾病疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国感染疾病疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Moderna, Inc.
    • AstraZeneca plc
    • Johnson & Johnson
    • BioNTech SE
    • CSL Limited
    • Sinovac BIoTech Ltd.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market is projected to grow by USD 66.98 billion at a CAGR of 9.74% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 31.83 billion
Estimated Year [2025] USD 34.88 billion
Forecast Year [2032] USD 66.98 billion
CAGR (%) 9.74%

A concise introduction outlining how scientific advances and operational evolution are reshaping infectious vaccine development pathways and delivery models

The infectious vaccines landscape is undergoing a transformative phase driven by scientific innovation, evolving public health priorities, and shifting operational practices. Over the last decade, advances in platform technologies such as mRNA and viral vectors have matured from experimental modalities into clinically validated tools, prompting broader interest across preventive and therapeutic indications. Concurrently, established modalities including conjugate, inactivated, live attenuated, subunit, and toxoid vaccines continue to evolve through formulation improvements, combination strategies, and targeted antigen design.

Emerging manufacturing techniques, improved cold chain management, and digital supply chain visibility are enabling more reliable distribution across diverse healthcare settings. Regulatory pathways are adapting to accommodate novel platforms while maintaining rigorous safety and efficacy standards, and public health programs are increasingly prioritizing broader vaccine access and adult immunization strategies. As a result, stakeholders from biopharma developers to public immunization programs are recalibrating product development, partnership, and deployment plans to reflect both technological promise and operational realities.

This introduction frames the report's focus on platform diversity, route-of-administration innovation, end-user dynamics across clinics, hospitals, pharmacies, and public health centers, and the distribution mechanisms that will shape uptake and impact. It sets the scene for detailed analysis that follows, identifying where scientific opportunity intersects with commercial and public health imperatives.

An exploration of converging technological, regulatory, and distributional shifts that are driving rapid evolution in vaccine development and deployment practices

The landscape for infectious vaccines is being reshaped by a set of converging shifts that extend beyond scientific breakthroughs to influence regulatory expectations, supply networks, and care delivery models. First, platform diversification is accelerating: messenger RNA technologies and viral vectors have moved from proof-of-concept to scalable manufacturing, while self-amplifying RNA and refined lipid nanoparticle formulations are increasing the range of feasible indications. Established platforms such as conjugate, inactivated, and toxoid vaccines are not standing still; they are benefitting from antigen engineering, adjuvant optimization, and novel presentation formats that improve immunogenicity and durability.

Second, administration routes are expanding in importance. Intramuscular delivery remains dominant for many programs, yet intradermal, intranasal, oral, and subcutaneous options are attracting renewed attention because they can improve patient acceptance, simplify logistics, or confer mucosal immunity. Third, end-user segmentation is influencing distribution strategies: clinics, hospitals, pharmacies, and public health centers each present distinct operational constraints and opportunities, shaping packaging, cold chain requirements, and digital record integration. Fourth, distribution channels are fragmenting and specializing, with government procurement, hospital pharmacies, online pharmacies, and retail outlets each requiring tailored commercial approaches.

Together, these shifts create a dynamic environment where agility in development and distribution, coupled with strategic partnerships and regulatory foresight, will determine which programs achieve broad and sustained adoption.

A pragmatic assessment of how 2025 tariff measures are reshaping supply chains, sourcing strategies, and procurement dynamics across vaccine manufacturing and distribution

The introduction of tariffs affecting vaccine inputs, components, and related consumables in 2025 has introduced a new operational variable for manufacturers, distributors, and procurement agencies. Tariff policies influence unit cost structures across the value chain, driving manufacturers to re-evaluate global sourcing strategies, prioritize localized production where feasible, and accelerate supplier qualification processes to maintain resilience. In parallel, procurement organizations and public health purchasers have responded by reassessing supplier diversification and by placing greater emphasis on contractual safeguards to mitigate supply disruptions.

Tariffs also affect the economics of distribution channels. Hospital pharmacies, retail and online pharmacies, and government procurement entities must integrate additional cost and compliance considerations into purchasing decisions, which can alter relative attractiveness of imported versus domestically produced products. For clinical developers, the cumulative cost effects have incentivized consideration of regional manufacturing partnerships and technology transfer agreements to reduce exposure to tariff-related volatility.

From a downstream perspective, routes of administration that reduce reliance on specialized cold chain components or disposable delivery devices may gain pragmatic appeal because they can lower the exposure to tariff-driven cost increases for ancillary supplies. Overall, the tariff landscape in 2025 underscores the importance of supply chain transparency, contractual flexibility, and proactive engagement with procurement bodies to preserve access while protecting margins and continuity of supply.

In-depth segmentation insights revealing how vaccine platform choices, administration routes, end-user settings, and distribution channels interact to shape adoption outcomes

Segment-level dynamics reflect pronounced heterogeneity across vaccine types, administration routes, end users, and distribution channels, and understanding these distinctions is essential for strategic prioritization. Across vaccine types, conjugate approaches-spanning Hib conjugate, meningococcal conjugate, and pneumococcal conjugate formats-remain essential for pediatric and high-risk adult programs where long-term immunogenicity and herd protection are priorities. Inactivated platforms, including hepatitis A, influenza, polio, and rabies formulations, continue to be widely used due to established safety profiles and broad regulatory familiarity. Live attenuated vaccines such as influenza live formulations, measles, oral polio, rubella, and varicella offer potent immune responses and are central to mass immunization campaigns but require careful handling and cold chain management. mRNA technologies, differentiated into lipid nanoparticle mRNA and self-amplifying mRNA, are rapidly expanding into new indications because of their development speed and antigen design flexibility. Subunit approaches, including protein subunit and virus-like particle constructs, provide attractive safety and manufacturability attributes, while toxoid vaccines targeting diphtheria, pertussis, and tetanus remain pillars of many immunization schedules. Viral vectors such as adenovirus, MVA, and VSV continue to be leveraged for their ability to elicit strong cellular immunity in both prophylactic and therapeutic contexts.

When considering routes of administration, intradermal, intramuscular, intranasal, oral, and subcutaneous options create differing operational demands and patient experiences that influence adoption in clinics, hospitals, pharmacies, and public health centers. End-user settings vary widely: clinics encompassing general practice and specialty care have different throughput and storage needs compared with hospitals, where private and public institutions have distinct procurement and formulary processes; pharmacies operate across online and retail formats with unique customer interfaces; and public health centers in rural and urban settings confront divergent logistical constraints. Distribution channels-government agencies divided into local and national tiers, hospital pharmacies operating in-hospital and outpatient services, online pharmacies delivering direct and platform-mediated sales, and retail pharmacies split between chain and independent models-further shape commercial approaches. These segmentation dimensions interact; for example, a protein subunit vaccine delivered intramuscularly for adult use may follow a distinct distribution and procurement path than an intranasal live attenuated pediatric vaccine procured through national public health tenders.

Recognizing these interdependencies enables stakeholders to align development, manufacturing, and commercialization strategies with the specific requirements of target segments, reducing time to adoption and enhancing operational fit.

Key regional considerations explaining how distinct healthcare infrastructures and regulatory environments in the Americas, EMEA, and Asia-Pacific shape vaccine strategy

Regional dynamics exert a strong influence on product design, regulatory strategy, manufacturing footprint, and deployment priorities. In the Americas, established immunization programs and well-developed private and public healthcare infrastructures support advanced distribution channels such as hospital pharmacies and extensive retail and online pharmacy networks, while also providing fertile ground for next-generation platforms and adult immunization initiatives. Consequently, developers often prioritize regulatory alignment and payer engagement strategies that reflect both private market mechanisms and large-scale public health procurement processes.

Europe, Middle East & Africa present a mosaic of regulatory frameworks, public health priorities, and supply chain capabilities. In parts of Europe, sophisticated regulatory pathways and manufacturing clusters allow for rapid adoption of novel platforms, whereas regions across the Middle East and Africa may prioritize thermostable formulations, simplified administration routes, and partnership models that support local capacity building to address access constraints. Public health centers in rural and urban areas across this region demand flexible cold chain solutions and deployment strategies that can operate under variable infrastructure conditions.

Asia-Pacific encompasses a wide spectrum from advanced manufacturing hubs to rapidly developing public health systems. Countries with strong biotech ecosystems are investing heavily in mRNA, viral vector, and next-generation manufacturing capabilities, while others focus on broadening routine immunization with established conjugate, inactivated, and toxoid vaccines. Across the region, there is heightened interest in technologies and distribution models that reduce supply chain vulnerability, enable local production, and support rapid scale-up during outbreaks. Taken together, regional priorities influence product specifications, regulatory timelines, and supply chain investments, making geographic strategy a central component of any vaccine program.

A strategic synthesis of how companies and partners are aligning platform investments, manufacturing capabilities, and collaborative ecosystems to secure competitive advantage

Leading organizations across biopharma, biotech, and contract manufacturing are redefining competitive positioning through combinations of platform investment, strategic alliances, and capacity expansion. Some developers are focusing on platform extensibility, meaning they are building capabilities to repurpose mRNA, viral vector, or protein subunit platforms for multiple indications to maximize development efficiency. Contract development and manufacturing organizations are expanding fill-finish and modular production capabilities to meet demand for both traditional and novel vaccine formats, with attention to cold chain innovations and single-use technologies.

Collaborative ecosystems are increasingly central: alliances between large pharmaceutical companies, regional manufacturers, and technology specialists facilitate technology transfer, local production, and regulatory navigation. In parallel, specialized suppliers of lipid nanoparticles, adjuvants, and analytical services are gaining importance as strategic partners because they provide critical inputs that affect product performance and manufacturability. Clinical and regulatory consultancies that can support accelerated clinical pathways and dossier preparation across diverse jurisdictions are also valued partners.

Finally, surveillance and real-world evidence providers that integrate immunization registries, adverse event monitoring, and epidemiological data are becoming strategic assets for companies seeking to demonstrate value, optimize post-approval programs, and support targeted vaccination campaigns. Collectively, these trends underscore the need for a coordinated approach to partnerships, capacity planning, and technology investment to maintain competitiveness in a complex and fast-evolving landscape.

Actionable recommendations that combine platform flexibility, manufacturing resilience, and targeted commercial engagement to enhance adoption and mitigate operational risk

Industry leaders should adopt a multi-dimensional strategy that balances technological innovation, operational resilience, and market-tailored deployment. Prioritizing platform flexibility enables organizations to pivot development resources across indications and respond quickly to emerging pathogen threats. At the same time, investing in manufacturing resilience - including localized production, diversified supplier networks, and modular fill-finish capacity - reduces exposure to external shocks and tariff-driven cost variability. Leaders should also evaluate route-of-administration innovations that can lower logistics complexity, improve patient acceptance, or enable needle-free delivery programs in community settings.

Commercially, aligning distribution strategies with the needs of specific end users and channels will accelerate adoption. For instance, engaging early with hospital formulary committees, retail pharmacy chains, and public health purchasers can clarify storage and packaging requirements and inform pricing and contracting approaches. Regulatory foresight is equally important: proactive dialogue with authorities and investment in harmonized dossier development expedite approvals across multiple jurisdictions. Finally, establishing data partnerships for post-market surveillance and real-world effectiveness monitoring strengthens value demonstrations and supports sustained uptake.

By combining platform versatility, supply chain robustness, targeted commercial engagement, and evidence-generation commitments, industry leaders can position their portfolios to capture clinical and public health opportunities while mitigating operational risks.

A transparent summary of research sources and analytical approaches used to evaluate platform performance, supply chain risks, and stakeholder segmentation across vaccine programs

This research synthesizes public scientific literature, regulatory guidance documents, industry technical reports, and structured interviews with subject-matter experts across development, manufacturing, regulatory affairs, and procurement. Primary qualitative inputs were collected through discussions with leaders in vaccine development, contract manufacturing organizations, supply chain specialists, and public health procurement officers to capture operational realities and strategic priorities. Secondary research encompassed peer-reviewed journals, regulatory agency communications, and technical white papers focused on platform technologies, administration routes, and distribution innovations.

Analysis methodologies included comparative platform assessment, supply chain risk mapping, and stakeholder segmentation to identify critical interdependencies among vaccine types, routes of administration, end-user requirements, and distribution channels. Scenario-based evaluation was applied to assess the operational implications of policy changes such as tariff measures, and to explore strategic responses including localization, supplier diversification, and alternative packaging strategies. Wherever possible, findings were cross-validated across multiple sources to ensure robustness, and expert validation sessions were conducted to refine key insights and practical recommendations.

This approach provides a holistic view of technological potential, operational constraints, and commercial pathways without relying on proprietary market estimates, enabling decision-makers to draw practical conclusions for strategy and investment.

A conclusive synthesis emphasizing the need for integrated scientific, manufacturing, and commercial strategies to convert technology advances into reliable public health impact

Infectious vaccines occupy a rapidly evolving intersection of science, policy, and logistics, where success depends on integrating technological capabilities with pragmatic delivery strategies. Platform diversity-from conjugate and inactivated vaccines to mRNA, viral vectors, subunit constructs, and toxoids-offers multiple pathways to address unmet needs, while administration route innovations open possibilities for improved population-level protection and easier deployment. However, these scientific opportunities must be balanced against operational realities including cold chain constraints, procurement mechanisms, and the regulatory landscape.

The cumulative impact of policy actions, such as the tariff measures introduced in 2025, highlights the need for supply chain transparency and flexible sourcing approaches. Regional differences in infrastructure and regulatory maturity further underscore the importance of tailoring strategies to geographic context. Ultimately, organizations that align platform selection with end-user needs, invest in resilient and scalable manufacturing, and engage proactively with payers and public health stakeholders will be best positioned to translate scientific advances into widespread, sustainable public health impact.

This conclusion emphasizes the imperative for coordinated action across R&D, manufacturing, and commercial functions to realize the potential of next-generation vaccines while ensuring equitable and reliable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in mRNA vaccine technology enabling rapid development of targeted infectious disease immunizations
  • 5.2. Expansion of thermostable vaccine formulations supporting distribution of infectious vaccines in resource limited regions
  • 5.3. Integration of next generation adjuvants to enhance immunogenicity and durability of infectious disease vaccines
  • 5.4. Emergence of combination vaccines addressing multiple pathogens to streamline immunization schedules globally
  • 5.5. Increasing collaboration between public and private sectors to fund and accelerate infectious vaccine pipelines
  • 5.6. Adoption of genomic surveillance data to inform real time vaccine strain selection and update strategies
  • 5.7. Implementation of digital cold chain monitoring solutions ensuring potency of vaccines across distribution networks
  • 5.8. Regulatory frameworks evolving to expedite review and approval of innovative infectious vaccine platforms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
    • 8.1.1. Hib Conjugate
    • 8.1.2. Meningococcal Conjugate
    • 8.1.3. Pneumococcal Conjugate
  • 8.2. Inactivated
    • 8.2.1. Hepatitis A
    • 8.2.2. Influenza
    • 8.2.3. Polio
    • 8.2.4. Rabies
  • 8.3. Live Attenuated
    • 8.3.1. Influenza Laiv
    • 8.3.2. Measles
    • 8.3.3. Oral Polio
    • 8.3.4. Rubella
    • 8.3.5. Varicella
  • 8.4. MRNA
    • 8.4.1. Lipid Nanoparticle MRNA
    • 8.4.2. Self-Amplifying MRNA
  • 8.5. Subunit
    • 8.5.1. Protein Subunit
    • 8.5.2. Virus-Like Particle
  • 8.6. Toxoid
    • 8.6.1. Diphtheria
    • 8.6.2. Pertussis
    • 8.6.3. Tetanus
  • 8.7. Viral Vector
    • 8.7.1. Adenovirus
    • 8.7.2. MVA
    • 8.7.3. VSV

9. Infectious Vaccines Market, by Route Of Administration

  • 9.1. Intradermal
  • 9.2. Intramuscular
  • 9.3. Intranasal
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Infectious Vaccines Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Practice
    • 10.1.2. Specialty
  • 10.2. Hospitals
    • 10.2.1. Private
    • 10.2.2. Public
  • 10.3. Pharmacies
    • 10.3.1. Online
    • 10.3.2. Retail
  • 10.4. Public Health Centers
    • 10.4.1. Rural
    • 10.4.2. Urban

11. Infectious Vaccines Market, by Distribution Channel

  • 11.1. Government Agencies
    • 11.1.1. Local
    • 11.1.2. National
  • 11.2. Hospital Pharmacies
    • 11.2.1. In-Hospital
    • 11.2.2. Outpatient
  • 11.3. Online Pharmacies
    • 11.3.1. Direct
    • 11.3.2. Platform
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain
    • 11.4.2. Independent

12. Infectious Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infectious Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infectious Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. GlaxoSmithKline plc
    • 15.3.4. Sanofi S.A.
    • 15.3.5. Moderna, Inc.
    • 15.3.6. AstraZeneca plc
    • 15.3.7. Johnson & Johnson
    • 15.3.8. BioNTech SE
    • 15.3.9. CSL Limited
    • 15.3.10. Sinovac Biotech Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NA